Insider Trading Alert - PCH, PBPB And WST Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Friday, May 22, 2015, 89 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $1,297.00 to $237,892,500.00.

Highlighted Stocks Traded by Insiders:

Potlatch (PCH) - FREE Research Report

Grenier Charles P, who is Director at Potlatch, bought 2,000 shares at $35.80 on May 22, 2015. Following this transaction, the Director owned 2,000 shares meaning that the stake was boosted by 100% with the 2,000-share transaction.

The shares most recently traded at $36.31, up $0.51, or 1.4% since the insider transaction. Historical insider transactions for Potlatch go as follows:

  • 4-Week # shares bought: 2,000
  • 12-Week # shares bought: 2,000
  • 24-Week # shares bought: 2,000

The average volume for Potlatch has been 215,400 shares per day over the past 30 days. Potlatch has a market cap of $1.5 billion and is part of the financial sector and real estate industry. Shares are down 13.71% year-to-date as of the close of trading on Friday.

Potlatch Corporation operates as a real estate investment trust (REIT) that owns and manages timberlands located in Arkansas, Idaho, Minnesota and Wisconsin in the United States. The stock currently has a dividend yield of 4.15%. The company has a P/E ratio of 19.6. Currently, there are 4 analysts who rate Potlatch a buy, 2 analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PCH - FREE

TheStreet Quant Ratings rates Potlatch as a buy. Among the primary strengths of the company is its respectable return on equity which we feel is likely to continue. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Potlatch Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Potbelly Corporation (PBPB) - FREE Research Report

Keil Bryant L, who is Director at Potbelly Corporation, sold 5,000 shares at $13.98 on May 22, 2015. Following this transaction, the Director owned 447,672 shares meaning that the stake was reduced by 1.1% with the 5,000-share transaction.

The shares most recently traded at $13.90, down $0.08, or 0.58% since the insider transaction. Historical insider transactions for Potbelly Corporation go as follows:

  • 4-Week # shares bought: 15,800
  • 4-Week # shares sold: 5,000
  • 12-Week # shares bought: 15,800
  • 12-Week # shares sold: 15,425
  • 24-Week # shares bought: 15,800
  • 24-Week # shares sold: 150,000

The average volume for Potbelly Corporation has been 327,500 shares per day over the past 30 days. Potbelly Corporation has a market cap of $413.4 million and is part of the services sector and leisure industry. Shares are up 7.07% year-to-date as of the close of trading on Friday.

Potbelly Corporation, through its subsidiaries, owns and operates Potbelly Sandwich Works sandwich shops in the United States. It also sells and administers franchises of new Potbelly Sandwich Works sandwich shops. The company has a P/E ratio of 81.1. Currently, there are 2 analysts who rate Potbelly Corporation a buy, 2 analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PBPB - FREE

TheStreet Quant Ratings rates Potbelly Corporation as a sell. The company's weaknesses can be seen in multiple areas, such as its generally disappointing historical performance in the stock itself and poor profit margins. Get the full Potbelly Corporation Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

West Pharmaceutical Services (WST) - FREE Research Report

Green Eric Mark, who is Chief Executive Officer at West Pharmaceutical Services, bought 18,300 shares at $54.89 on May 22, 2015. Following this transaction, the Chief Executive Officer owned 18,300 shares meaning that the stake was boosted by 100% with the 18,300-share transaction.

The shares most recently traded at $54.34, down $0.55, or 1.01% since the insider transaction. Historical insider transactions for West Pharmaceutical Services go as follows:

  • 4-Week # shares bought: 18,300
  • 4-Week # shares sold: 20,000
  • 12-Week # shares bought: 18,300
  • 12-Week # shares sold: 20,000
  • 24-Week # shares bought: 18,300
  • 24-Week # shares sold: 25,000

The average volume for West Pharmaceutical Services has been 319,000 shares per day over the past 30 days. West Pharmaceutical Services has a market cap of $4.0 billion and is part of the health care sector and health services industry. Shares are up 3.55% year-to-date as of the close of trading on Friday.

West Pharmaceutical Services, Inc. develops, manufactures, and sells components and systems for the packaging and delivery of injectable drugs, as well as delivery system components for the pharmaceutical, healthcare, and consumer products industries. The stock currently has a dividend yield of 0.8%. The company has a P/E ratio of 30.3. Currently, there is 1 analyst who rates West Pharmaceutical Services a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on WST - FREE

TheStreet Quant Ratings rates West Pharmaceutical Services as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures and reasonable valuation levels. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full West Pharmaceutical Services Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Comcast's Brian Roberts vs. Disney's Bob Iger: Which Titan Will Nab Fox?

Comcast's Brian Roberts vs. Disney's Bob Iger: Which Titan Will Nab Fox?

Online Retailers Hit by Supreme Court Ruling Requiring Sales Tax Collection

Online Retailers Hit by Supreme Court Ruling Requiring Sales Tax Collection

Dow Logs Eighth Straight Drop as Stocks Slump

Dow Logs Eighth Straight Drop as Stocks Slump

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

U.S. Markets 'Definitively' Missing Out on Capital by Barring Cannabis Companies

U.S. Markets 'Definitively' Missing Out on Capital by Barring Cannabis Companies